Immune checkpoint inhibitors have now entered the treatment landscape for cutaneous T-cell lymphoma (CTCL). In this interview, Christiane Querfeld, MD, PhD, of City of Hope, Duarte, CA, discusses a Phase I/II clinical trial of a PD-L1 inhibitor for CTCL. Dr Querfeld covers the response rates and what these indicate for the treatment of CTCL with immune checkpoint inhibitors. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Immune checkpoint inhibitors for cutaneous T-cell lymphoma
